The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
Barriers and facilitators to seeking care for the initial diagnosis of melanoma in an urban safety-net hospital. Time Impact on time related to treatment, travel, personal, work or social activities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results